Clinical trials: Depression NOS
Depression, Post-Traumatic Stress Disorder
Improving Quality-of-life and Depressive Symptoms of Combat Veterans Via Internet-based Intervention
Background: Current military involvement in Afghanistan (Operation Enduring Freedom - OEF) and Iraq (Operation Iraqi Freedom - OIF) has created unforeseen burdens on the mental health and well-being of US service women and men.
- Conditions
- Depression, Post-Traumatic Stress Disorder, Functional Status
- Trial name
- NCT01231711
- Testing
- Vets Prevail
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Prevail Health Solutions, LLC
Bipolar Disorder Depression
Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults
The goal of this clinical trial is to learn if ABX-002 added to participants' existing treatment(s) can improve clinical symptoms of depression and to learn about potential effects on brain chemistry that may correlate with…
- Trial name
- NCT06869187
- Testing
- ABX-002
- Where
- 14 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Autobahn Therapeutics, Inc.
Depression, Anxiety
C-STRESS: A Mental Health App for College Students With Depression
The goal of this pilot study is to examine the feasibility of the prototype C-STRESS app with 3 college students from UCI with clinically significant depression (scored ≥ 10 on the Patient Health Questionnaire-9).
- Conditions
- Depression, Anxiety, Stress, Psychological, Mobile Phone Use
- Trial name
- C-STRESS (NCT05776901)
- Testing
- C-STRESS
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Benten Technologies, Inc.
Atypical Depression
St. John's Wort Extract LI 160 for the Treatment of Atypical Depression
The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.
- Trial name
- NCT00861978
- Testing
- St. John's Wort extract
- Volunteers
- 201 people
- Sponsor
- Cassella-med GmbH & Co. KG
Bipolar Depression, Bipolar I Disorder
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)
X-CEED-OLE is a Phase 3, multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner in adult participants who successfully completed an antecendent Phase 3 azetukalner bipolar…
- Conditions
- Bipolar Depression, Bipolar I Disorder, Bipolar Disorder, Bipolar II Disorder
- Trial name
- NCT07217860
- Testing
- Azetukalner
- Where
- 20 sites in United States
- Volunteers
- 400 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Major Depressive Disorder
Safety Study of F2695 SR in Major Depressive Disorder
The purpose of this study is to evaluate the long- term safety of F2695-SR in the treatment of adults with major depressive disorder.
- Trial name
- LVM-MD-04 (NCT01034267)
- Testing
- F2695 SR
- Where
- 68 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Alzheimer's Disease, Traumatic Brain Injury
Clinical Evaluation of Flortaucipir F 18
This study is designed to expand the database of flortaucipir F 18 safety and tau binding as measured by PET imaging and to provide standardized conditions for flortaucipir PET use, data collection and analysis to facilitate…
- Conditions
- Alzheimer's Disease, Traumatic Brain Injury, Depression
- Trial name
- NCT02278367
- Testing
- Flortaucipir F18, Brain PET scan
- Where
- 5 sites in United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals
Major Depressive Disorders
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Primary objective is to demonstrate the antidepressant efficacy on the Hamilton depression rating scale (HAM-D) of amibegron (SR58611) 700 mg/day compared to placebo in the treatment of patients with a recurrent major depressive…
- Trial name
- NCT00825019
- Testing
- amibegron (SR58611A), paroxetine
- Where
- United States
- Volunteers
- 306 people
- Sponsor
- Sanofi
Anxiety, Depression in Adolescence
Co-designing Adaptations of a Digital Mental Health Intervention (Wysa) for Adolescent Girls With Anxiety or Depression in Rural India
The goal of this study is to culturally and contextually adapt Wysa, an evidence-based AI-powered digital mental health intervention (DMHI), for adolescent girls (ages 13-18) with symptoms of anxiety and/or depression in rural…
- Conditions
- Anxiety, Depression in Adolescence, Anxiety Disorder of Adolescence
- Trial name
- NCT07595029
- Testing
- Digital psychosocial tool
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Wysa
Depression, Anxiety
Technology Enabled Mental Health Intervention for Individuals in the Criminal Justice System
In the United States, over 60% of the 2.2 million people who are incarcerated struggle with mental health problems. Currently, correctional facilities are limited in their ability to provide care.
- Conditions
- Depression, Anxiety, Mood
- Trial name
- NCT03105973
- Testing
- Technology-Enabled CBT Treatment
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Jail Education Solutions, Inc.
Schizophrenia, Bipolar Disorder
ADH.E.R.E.: Therapeutic ADHerence and Treatment Strategies: A Mental Health Registry
The purpose of this study is to find out how well new treatment plans are followed by outpatients with major mental illnesses (schizophrenia, bipolar disorder, depression, personality disorder) and to determine the relationship…
- Conditions
- Schizophrenia, Bipolar Disorder, Depression, Personality Disorder
- Trial name
- NCT00264069
- Testing
- antipsychotic, antidepressants
- Volunteers
- 2,622 people
- Sponsor
- Janssen-Cilag, S.A.
Smoking Cessation, Depression
Safety And Efficacy Of 12 Weeks Of Varenicline For Smoking Cessation In Smokers With Depression
Patients with depression tend to have a higher prevalence of smoking as well as increased severity of nicotine dependence. Phase 2 and Phase 3 varenicline clinical trials that demonstrated its efficacy and tolerability have not…
- Trial name
- NCT01078298
- Testing
- varenicline
- Where
- 41 sites in United States, Bosnia and Herzegovina and 6 more
- Volunteers
- 525 people
- Sponsor
- Pfizer
Treatment Resistant Depression
A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
The purpose of this study is to assess the efficacy and safety of olanzapine and fluoxetine compared to placebo and fluoxetine as treatment for treatment-resistant depression (TRD) in Chinese participants.
- Trial name
- NCT01687478
- Testing
- Olanzapine, Fluoxetine
- Where
- 11 sites in China
- Volunteers
- 176 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Autism
Pediatric Open-Label Extension Study
This is an open-label, 104-week, multicenter, extension study designed to evaluate the long-term safety, tolerability and effectiveness of flexibly dosed lurasidone (20, 40, 60 or 80 mg/day) in pediatric subjects who have…
- Conditions
- Schizophrenia, Autism, Bipolar Depression
- Trial name
- NCT01914393
- Testing
- Lurasidone 20, 40, 60, 80 mg, flexibly dosed
- Where
- 88 sites in United States, Bulgaria and 13 more
- Volunteers
- 702 people
- Sponsor
- Sumitomo Pharma America, Inc.
Bipolar Depression, Suicidal Ideation
NRX101 Glx Biomarker Validation Study
Subnormal level of Glutamate+Glutamine (Glx) in the Anterior Cingulate Cortex (ACC) of the brain has been associated with depression and PTSD.
- Trial name
- NRX-GLX (NCT03402152)
- Testing
- NRX-101, Lurasidone HCl
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NeuroRx, Inc.
Depressive Disorder, Depressive Symptoms
AI Mental Health Tool vs. Psychoeducation Control
The goal of this clinical trial is to learn if Ash, an AI chat tool for mental health, works better than static psychoedcuation in reducing mental health symptoms.
- Trial name
- NCT07841483
- Testing
- Ash, Psychoeducation
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Slingshot AI
Treatment Resistant Depression
A Randomized, Placebo-Controlled, Double-Blind Study to Assess Safety and Efficacy of PCN-101 in TRD
This is a double-blind, randomized, placebo-controlled, multicenter study comprised of 3 phases:screening (up to 2 weeks [Day -15 to Day -2]), In-Clinic Treatment (Day -1 to Day 2; including double-blind treatment [Day 1]), and…
- Trial name
- NCT05414422
- Testing
- PCN-101
- Where
- 21 sites in United States, Germany and 1 more
- Volunteers
- 102 people
- Sponsor
- Perception Neuroscience
Major Depressive Disorder
Study of Technology-assisted Treatment of Adolescent Depression
The purpose of this study is to evaluate a computer-guided, telephone-based therapy for adolescent depression, delivered in a pediatric primary setting in the community.
- Trial name
- iTAD (NCT01582581)
- Testing
- Telephonic CBT, Wait List Control
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- iHope Network, Inc.
Bipolar Depression
Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression
This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe for the treatment of patients with bipolar I depression
- Trial name
- NCT00868959
- Testing
- lurasidone
- Where
- 151 sites in United States, Canada and 13 more
- Volunteers
- 817 people
- Sponsor
- Sumitomo Pharma America, Inc.
Depression
A Feasibility Study of an AI-Powered Clinical Decision Aid for Personalized Depression Treatment Selection
The Clinical Decision Aid (CDA) is a predictive model that takes as input individual patient characteristics, called 'features', which are inputted by the physician or by patient self-report, and outputs a list of possible…
- Trial name
- NCT04061642
- Testing
- Clinical Decision Aid
- Where
- Canada
- Volunteers
- 17 people
- Sponsor
- Aifred Health Inc.